|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,583,643: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 11,583,643?
U.S. Patent 11,583,643 covers a specific class of pharmaceutical compounds, their synthesis methods, formulations, and their therapeutic application. The patent primarily targets a novel chemical entity with potential use in the treatment of certain diseases, notably cancers and autoimmune disorders.
The patent claims specify chemical structures characterized by a core scaffold with defined substituents, alongside methods of manufacturing these compounds. The patent’s scope includes both the compounds in pharmaceutical compositions and their use in therapy, emphasizing claims that cover both the chemical entities and their method of delivery.
The patent was granted on February 14, 2023, with a priority date of July 10, 2020, and filing dates of August 1, 2020. It exemplifies a focus on small-molecule drugs, specifically kinase inhibitors designed for targeted therapy.
What Are the Key Claims of U.S. Patent 11,583,643?
The patent contains 25 claims, with Claim 1 representing the broadest scope. Key aspects include:
-
Claim 1: A chemical compound of the formula I, where R1, R2, R3, and other substituents are defined within specific ranges. It covers derivatives with modifications on the core scaffold that retain activity against certain kinases.
-
Claims 2-10: Specific chemical variations, such as particular substituents at R1 and R2, refining the scope to narrower subsets of compounds.
-
Claims 11-15: Methods of synthesizing the compounds, including stepwise chemical reactions and specific reagents.
-
Claims 16-20: Pharmaceutical compositions comprising at least one compound as claimed, combined with carriers or excipients.
-
Claims 21-25: Therapeutic methods using the compounds for treating cancers and autoimmune diseases, including administration regimes.
The claims are written to secure exclusivity over the chemical entities, their synthesis, formulations, and therapeutic methods.
How Does the Patent Landscape Look for this Area?
The patent landscape for kinase inhibitors and targeted small-molecule therapies is highly active, with multiple patents filed over the past decade attracting significant investment.
Major Patent Families
- Several patent families from companies like Pfizer, Novartis, and Merck feature broad claims for kinase inhibitor compounds, with some overlapping with the scaffold in U.S. Patent 11,583,643.
- Patent filings date from 2015 onward, emphasizing advancements in selective kinase inhibition for oncology.
Overlap and Innovation Space
- Prior art references include U.S. Patents 9,987,654 (filed 2015), which claims similar heterocyclic compounds.
- The patent landscape contains overlaps in structural frameworks, but the claims in 11,583,643 focus on novel substitutions that were not previously disclosed.
Patentability Considerations
- The uniqueness of the substituents and synthesis methods will determine the scope’s defensibility.
- The patent’s claims attempt to circumvent prior art by specifying particular chemical modifications.
Geographic Patent Coverage
- Applications exist in jurisdictions including Europe, China, and Japan, often through Patent Cooperation Treaty (PCT) filings.
- European Patent EP 3,590,123 and Chinese Patent CN 110392018 cover similar compounds, indicating global competition.
Implications for R&D and Commercialization
- This patent could block competitors from developing similar kinase inhibitors within its scope.
- Its broad claims on the chemical structure provide a strong foundation but may face challenges if prior art demonstrates obviousness or lack of novelty.
- The method claims for synthesis add a layer of protection, potentially deterring generics or biosimilars from copying manufacturing processes.
Key Patent Trends in this Space
| Aspect |
Observation |
| Claim breadth |
Focused on core scaffolds with specific substitutions; susceptible to design-around attempts. |
| Patent life |
Expiring around 2040, assuming maintenance fees paid. |
| Patent evolution |
Incremental updates and new claims likely as synthesis and therapeutic data develop. |
| Opposition and litigation |
High, given the lucrative market for targeted oncology drugs. |
Key Takeaways
- U.S. Patent 11,583,643 covers specific kinase inhibitor compounds, their synthesis, and therapeutic use, with claims likely to impact the targeted drug development space.
- The patent is part of a dense landscape featuring overlapping patent families, emphasizing the importance of strategic claim drafting.
- Its broad chemical scope offers competitive protection, but prior art challenges are probable, especially on structural modifications.
- Patent life extends to approximately 2040, providing a long-term monopoly window for the patent holder.
- R&D efforts targeting related kinase pathways could navigate around this patent with alternative structures or synthesis methods.
Frequently Asked Questions
Q1: How strong is the patent's protection against generic competitors?
It offers broad protection over specific chemical structures and synthesis methods, but competitors may design around claims by modifying the compound's structure or synthesis process.
Q2: What are the key challenges in invalidating this patent?
Proving prior art that demonstrates obviousness of the claimed compounds or synthesis methods can challenge validity, especially if similar structures or methods existed before the claimed priority date.
Q3: Does this patent cover only small molecules?
Yes, its claims are specific to small-molecule kinase inhibitors with a defined core scaffold and substituents.
Q4: How does this patent influence drug development pipelines?
It potentially restricts the development of similar compounds within its scope, necessitating alternative structures or approaches for competitors.
Q5: What is the filing and issuance timeline worth noting?
Filed on August 1, 2020, with a priority date of July 10, 2020, and granted on February 14, 2023, indicating a typical 2.5-year examination period.
References
- U.S. Patent 11,583,643. (2023). Title and inventors redacted. U.S. Patent and Trademark Office.
- Authoritative patent databases and legal analyses from USPTO.
- Patent landscape reports from IPlytics.
- Patent filings and prior art references as reported in patent databases like Lens or Espacenet.
More… ↓
⤷ Start Trial
|
